Basic Information
| ID | DRAMP21235 |
|---|
| Sequence | WKRIVRWIKRWLR |
|---|
| Length | 13 |
|---|
| Name | FK13-a2 (Derived from FK13) |
|---|
| Source | Synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram- |
|---|
| Pathogen | [Ref.28161291] Gram-positive bacteria : Bacillus subtilis(KCTC 3068)(MIC=4 μM), Staphylococcus epidermidis(KCTC 1917)(MIC=8 μM), Staphylococcus aureus(KCTC1621)(MIC=2 μM);##Gram-negative bacteria : Escherichia coli(KCTC 1682)(MIC=8 μM), Pseudomonas aeruginosa(KCTC 1637)(MIC=4 μM), Salmonella typhimurium(KCTC 1926)(MIC=4 μM) |
|---|
| Hemolytic Activity | [Ref.28161291] HC50=14.0 μM against human red blood cells |
|---|
| Cytotoxicity | [Ref.28161291] The cell viability of mouse macrophage RAW264.7 induced by FK13-a2 is 104.5%, 101.7%, 100.4%, 77.0%, 58.9% and 15.8% at peptide concentrations of 1.25, 2.5, 5, 10, 20 and 40 μM.## The cell viablity of human keratinocyte HaCaT induced by FK |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 28161291 |
|---|
